Abstract
We intend to use two specific cell surface tumor biomarkers, the prostate specific membrane antigen (PSMA) and the carcinoembryonic antigen (CEA), as targets for directing fluorescent probes, antitumor drugs, or therapeutic bacteria. For this, two previously described and characterized nanobodies will be used for targeting these cell surface biomarkers: the anti-PSMA nanobody called NB7 a…